In one paragraphArticle in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
20 authors.
Paula Jimenez-FonsecaMedical Oncology Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0003-4592-3813 Alberto Carmona-BayonasMedical Oncology Department, Hospital Universitario Morales Meseguer, Instituto Murciano de Investigación Biosanitaria (IMIB), University of Murcia, 30008 Murcia, Spain.ORCID 0000-0002-1930-9660 Amy Storfer-IsserAstellas Pharma, Inc., Northbrook, IL 60062, USA.
Marta Martin-RichardMedical Oncology Department, Catalan Institute of Oncology, 08908 L'Hospitalet, Spain.
Tamara SauriMedical Oncology Department, Hospital Clinic and Translational Genomics and Targeted Therapies in Solid Tumors IDIBAPS, 08036 Barcelona, Spain.
Juana María CanoMedical Oncology Department, Hospital General Universitario de Ciudad Real, 13005 Ciudad Real, Spain.
Elia Martínez MorenoMedical Oncology Department, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain.
Javier LópezMedical Oncology Department, Hospital Universitario Morales Meseguer, Instituto Murciano de Investigación Biosanitaria (IMIB), University of Murcia, 30008 Murcia, Spain.ORCID 0000-0002-5353-1847 Francisco Garcia NavalonMedical Oncology Department, Hospital Universitario Son Llatzer, 07198 Mallorca, Spain.ORCID 0009-0002-0013-4538 Lucía Gómez-GonzálezMedical Oncology Department, Hospital General Universitario de Alicante, 03010 Alicante, Spain.ORCID 0000-0003-1017-4568 Maribel Ruiz MartínMedical Oncology Department, Hospital Universitario Rio Carrión, 34005 Palencia, Spain.
Ana Belén Rupérez BlancoMedical Oncology Department, Hospital Universitario de Toledo, 45007 Toledo, Spain.ORCID 0000-0003-2338-4257 Flora López-LópezMedical Oncology Department, Hospital Universitario del Sureste, Arganda del Rey, 28500 Madrid, Spain.
Emilse Roncancio-DíazAstellas Pharma Europe Ltd., Addlestone KT15 2NX, UK.
Belén CorbachoAstellas Pharma Spain, 28046 Madrid, Spain.
Javier Gallego PlazasMedical Oncology Department, Hospital General Universitario de Elche, 03203 Alicante, Spain.ORCID 0000-0002-0584-1242 Funding
This study was sponsored by Astellas Pharma Europe Ltd. pending
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
adenocarcinomagastric neoplasmsgastroesophageal junctionHER2neoplasmssurvival
Identifiers
PMID40647463
PMCPMC12248623
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390